Introduction to Animal Models of Hyperuricemia

Hyperuricemia is a condition characterized by an abnormally elevated serum uric acid level, resulting from disturbances in purine metabolism and/or reduced uric acid excretion. In recent years, as living standards have improved and dietary patterns and lifestyle habits have changed, the incidence of hyperuricemia has been steadily increasing, with a noticeable trend toward younger ages of onset.

Service Advantages of the Aniphe BioLablogical Hyperuricemia Animal Model Platform

Our platform boasts mature techniques for establishing hyperuricemia models and a comprehensive suite of assays, fully capable of meeting diverse experimental and R&D requirements.

	The modeling methods are diverse. Classic induction methods, such as oxypurinol and adenine, can be adapted to suit various research settings.
	Model metrics are stable. Serum uric acid levels are markedly and persistently elevated, with a high modeling success rate, minimal inter-individual variability, and excellent reproducibility.
	Standardized Full-Process Quality Control Standardize animal husbandry and medication administration protocols, conduct regular monitoring of serum uric acid, renal function, and other relevant indicators, and ensure data traceability.
	Comprehensive testing system Supports multi-dimensional indicator assessment, including biochemical assays, histopathology, inflammation, and molecular biology.
	Experiments can be flexibly customized. Adjust the modeling cycle, drug dosage, and observation duration as needed to accommodate different experimental protocols.
	One-stop closed-loop service The entire workflow—from model establishment and intervention to assay—can be performed autonomously, enabling efficient delivery and supporting both basic research and preclinical regulatory submissions.

Modeling cycle	3–8 weeks
Laboratory animals	SPF-grade rats
Positive drug	Commonly used medications such as allopurinol, febuxostat, and benzbromarone can lower serum uric acid levels, improve metabolic parameters, and mitigate joint and renal damage.
Application areas	This model primarily investigates the pathogenic mechanisms underlying uric acid metabolism disorders, gouty arthritis, and renal injury caused by urate crystal deposition. It facilitates the screening of drugs with urate‑lowering, anti‑inflammatory, and analgesic effects, as well as the evaluation of their efficacy and safety. Additionally, it can be employed for target validation and for the development of natural products and innovative therapeutics, thereby supporting preclinical research and IND submissions.

Establishment of an Animal Model of Hyperuricemia

A composite modeling approach using adenine combined with potassium oxonate is employed: adenine is administered via feeding or injection to elevate uric acid precursors and enhance uric acid production, while potassium oxonate is used to inhibit uricase activity in the animal, thereby impeding uric acid catabolism. This method rapidly establishes a sustained hyperuricemia model, which may be accompanied by complications such as renal damage.

Model features:

The model takes a relatively long time to establish, but it exhibits clear and typical pathological features, making it suitable for research on gouty nephropathy and for evaluating the therapeutic efficacy of drugs in this condition.